IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures

MT Newswires Live

Yesterday

IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.

The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.

Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.

The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.

Price: 7.95, Change: +5.82, Percent Change: +273.24

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2644723293"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644723293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644723293?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644723293","market":"hk","top_or_hot":-1,"title":"IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures","media":"MT Newswires Live","content":"<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 02:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCM","symbol_name":"IceCure Medical Ltd.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644723293","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644723293","pubTimestamp":1781719747,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IceCure Medical  shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCM":"IceCure Medical Ltd.","BK4082":"医疗保健设备"},"translate_title":"乳腺癌冷冻消融手术商业采用的最新消息后，IceCure Medical股价上涨","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":1.5},"content_text":"IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}